We work with
humans for humans


Improving therapies. This is Sintetica. Simply and proudly.

We are fully committed to innovate therapies and drugs in anaesthesia, pain management, intensive care and neuromodulation.

In a world of constantly evolving healthcare challenges, we strive to develop novel drugs.

Sintetica has two production sites, both located in Switzerland and both specialised in the manufacture of liquid sterile injectable solutions.

Top quality products manufactured in Switzerland

Mendrisio

The Mendrisio plant focuses on the production of injectable drugs contained in ampoules, with two manufacturing lines: one dedicated to glass ampoules and one dedicated to polypropylene ampoules.

Couvet

The Couvet plant has one manufacturing line designated to the production of injectable drugs in polypropylene bags and another production line assigned to glass vials.

Sintetica in the world

Production
capacity per year

5’000’000

⎯⎯ infusion bags

8’000’000

⎯⎯ vials

90’000’000

⎯⎯ glass and polypropylene ampoules

Innovation


Is one of the guiding principles of how we operate to ensure that we continue to improve therapies and make an impact.

Innovate to improve

We engage with customers and clinicians to understand unmet needs. We think outside the box, challenge the status quo and accelerate the adoption of new solutions to change things for the better.

Our approach to innovation

Our Swiss Innovation Laboratory approach - uniquely designed with the contribution of our passionate KOLs - continues to deliver innovative drug formulations, providing best-in-class solutions to physicians in peri-operative and critical-care medicine, with unparalleled value to patients.

Innovation Cluster

It is an interdisciplinary team led by our Chief Innovation Cluster Officer, capable of proposing solutions that allow the company to reach the markets and patients by following, but also anticipating, the evolution of medical technologies and therapies.

Areas of focus


We offer a wide range of products in different therapeutic areas and medical settings such as anaesthesia, pain management, neuromodulation and intensive care.

Sintetica has developed a clear innovation strategy following patients’ needs and new sustainable pharma trends.

Corporate
Social
Responsibility

We strive to develop a culture in which respect is sovereign, lines of communications are opened, great talent is recognized and encouraged and individual success depends solely on personal merit and performance. Sintetica makes a great effort to be a positive member of the community everywhere it operates directly and is focused on minimizing the environmental impact of its operations by reducing its carbon footprint and natural resources demand.

  • Openness to people and to the world is a distinctive hallmark of Sintetica’s culture. In placing value on people, Sintetica sees the expression and foundation of its own culture and identity. We encourage and support human diversity in all its forms as an expression of richness and as a source of long-term development. We seek in every way to facilitate all forms of inclusion and encourage social and cultural contamination, promoting an inclusive environment that stimulates everyone's participation and encourages the exchange of ideas and perspectives.

  • Our people are our biggest asset. That’s why we aim to create an environment where solidarity, respect for the individual, open communication and passion for our work unleash the potential of all our people. We want our colleagues to be engaged, inspired and motivated by shared values and ambitions.

  • We are committed to environmental protection across the product lifecycle, from R&D, through manufacturing, marketing and ultimately disposal. We strive to minimize the environmental impact of our operations by reducing the carbon footprint and natural resource demands of our own and our suppliers' business activities.

Latest news

01

02

03